ABGSC acted as joint global coordinator and joint bookrunner in the NOK 300m equity issue in Thor Medical

On 4 September 2026, Thor Medical ASA (“Thor Medical” or the “Company”) announced the successful completion of a private placement and a retail offering, raising gross proceeds of NOK 300 million through the allocation of 62.5 million new shares at a subscription price of NOK 4.80 per share.

The private placement was multiple times oversubscribed with strong interest from both local and international investors. The net proceeds from the private placement and retail offering will be used to support the Company’s entry into the US market through the establishment of downstream production capabilities and commercial infrastructure for Pb-212, to expand and diversify feedstock access, as well as for working capital and other corporate purposes.

ABG Sundal Collier acted as Joint Global Coordinator and Joint Bookrunner in the private placement. We congratulate Thor Medical on the successful financing and would like to extend our gratitude for the vote of confidence.